Morena D’Alise

Company: Nouscom

Job title: Senior Vice President, Immunology

Seminars:

Nous-209 Vaccine: From Cancer Treatment to Interception in Lynch Syndrome Patients 9:00 am

Presenting NOUS-209, an off-the-shelf cancer vaccine encoding shared neoantigens across both sporadic and hereditary Microsatellite Instable (MSI) tumours Showing strong immunogenicity, breadth and durability of NOUS-209 induced immune response in patients with metastatic MSI tumours and Lynch Syndrome (LS) vaccinated patients Highlighting NOUS-209 Potential to ‘Intercept’ Cancer in Subjects with LSRead more

day: Day One